Doximity, Inc. (DOCS) Receives Equal-Weight Rating from Barclays: Potential Upside Ahead

On May 15, 2026, Barclays analyst Glen Santangelo assigned Doximity, Inc. (NYSE: DOCS) an “Equal-Weight” rating, implying that the stock is fairly valued at its current price of $18.01, with a target price of $20. This notable update comes amid a volatile trading environment and broader apprehension surrounding tech stocks, suggesting that investors should approach Doximity with caution while acknowledging its upside potential.

Recent Price Action

In recent trading sessions, Doximity’s stock exhibited significant movement, appreciating by approximately 6.27% or $1.14. The current price of $18.01 reflects a broader price correction, especially when considering its 52-week range, which turned rather stark with a high of $67.19 and a low of $6.67. The stock’s trading volume has ramped up recently, with 6.55 million shares exchanged, substantially above its average volume of 3.44 million shares. The company’s market capitalization stands at about $3.61 billion, supported by a beta of 1.353, indicating it is slightly more volatile than the market, which could explain recent investor sentiment and trading behavior.

Historical Performance

Doximity’s stock has had a challenging few months, reflecting broader market uncertainties. Over the past 30 days, the stock has seen a decline of 5.97%. The quarterly performance is even grimmer, plunging by 39.17%, while the annual return stands at -22.76%. Weekly volatility has reached 4.35%, indicating fluctuations in trader expectations and the stock’s reaction to market sentiment. An analysis of the last ten days shows an average trading volume of approximately 6.55 million shares, further compounding its volatile profile.

Earnings Analysis

Investors were met with disappointing earnings results as Doximity reported an actual earnings per share (EPS) of $0.10, which fell short of analysts’ expectations of $0.28, resulting in a surprise factor of -64.29%. This underperformance follows a more favorable previous quarter (EPS of $0.46 versus an estimated $0.44), raising concerns about the company’s earning momentum and commitment to growth. The disparity highlights the need for investors to carefully evaluate Doximity’s revenue streams and future earnings guidance.

Analyst / Consensus View

The sentiment among analysts is mixed, with a consensus of 23 ratings: 10 categorized as “Buy,” 13 as “Hold,” and no “Sell” recommendations. The average price target is set at $28.57, suggesting that analysts still see a potential upside for the stock. However, the most recent rating from Barclays places a more conservative view on the stock, as the target price of $20 aligns closely with its current trading level, hinting that substantial catalysts may be necessary to encourage renewed investor interest.

Stock Grading and Fundamental View

Doximity’s Stocks Telegraph Grading score stands at 53, indicating a generally stable but somewhat cautious investment outlook. This score reflects a moderate assessment of the company’s overall health, suggesting that while it may possess certain fundamental strengths, there are significant concerns regarding its earnings predictability and market position in light of competitor activities.

Conclusion

For investors considering Doximity, the stock may appeal to those seeking moderate growth with a willingness to tolerate volatility. Long-term investors might find the current valuation attractive given the analyst’s upside potential, while those with a more defensive investment strategy could remain cautious due to recent earnings performance and market fluctuations. Potential risks include ongoing volatility and competition in the digital healthcare space, emphasizing the need for vigilance and an understanding of market dynamics when managing a position in Doximity.